Madrigal Pharmaceuticals (MDGL) said Wednesday that patients with metabolic dysfunction-associated steatohepatitis treated with its Rezdiffra drug showed "marked reductions" in liver stiffness.
After two years of treatment with the drug, the vibration-controlled transient elastography results of 101 patients showed a statistically significant reduction in liver stiffness, the company said.
The late-stage trial of Rezdiffra included an open-label active treatment arm for patients with compensated MASH cirrhosis.
The company said 51% of the patients achieved a 25% or greater reduction in liver stiffness, which has been linked to a reduced progression to end-stage liver disease.
Madrigal said it plans to present additional trial results from the compensated MASH cirrhosis arm at a future medical conference.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.